<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00133471</url>
  </required_header>
  <id_info>
    <org_study_id>04-019</org_study_id>
    <nct_id>NCT00133471</nct_id>
  </id_info>
  <brief_title>Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults</brief_title>
  <official_title>Evaluation of the Reactogenicity and Immunogenicity of Four Dosage Levels of Intramuscular Monovalent Inactivated Influenza A/H9N2 Vaccine With and Without MF59 Adjuvant in Ambulatory Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the body's reactions and immune responses after&#xD;
      receiving different strengths of a H9N2 influenza virus vaccine with and without an adjuvant&#xD;
      given into the arm muscle. Study participants will include up to 96 healthy adults, ages&#xD;
      18-34. The 4 dosages of the experimental H9N2 vaccine to be tested in this study are the&#xD;
      following: 3.75, 7.5, 15, and 30-mcg (with and without MF59 adjuvant). Participants will be&#xD;
      vaccinated on Days 0 and 28. Participants will record any vaccine side effects in a diary for&#xD;
      7 days following each vaccination. Participants will return to the clinic on days 2 and 7&#xD;
      after vaccination. Blood samples will be collected 7 days following each vaccination. Serum&#xD;
      and nasal wash specimens will be collected before each vaccination and 4 weeks after&#xD;
      injections (0, 4, and 8 weeks). Participants will be involved in study related procedures for&#xD;
      up to 8 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this study is to assess the safety of 4 different dosages of purified&#xD;
      monovalent surface antigen (SA) influenza A/H9N2 virus vaccine with or without MF59 adjuvant&#xD;
      and administered intramuscularly to ambulatory adults. The hypothesis is that all dosage&#xD;
      levels of adjuvanted and nonadjuvanted vaccine will be well tolerated. The primary objective&#xD;
      of this project is to evaluate the safety of 4 dosage levels of monovalent surface antigen&#xD;
      (SA) influenza A/H9N2 virus vaccine given with or without MF59 adjuvant. The primary endpoint&#xD;
      is the frequency and severity of solicited local and systemic adverse events in each vaccine&#xD;
      dosage level group. The secondary objective of this project is to determine the&#xD;
      immunogenicity of 4 dosage levels of monovalent surface antigen (SA) influenza A/H9N2 virus&#xD;
      vaccine given with or without MF59 adjuvant. The secondary endpoints include the following:&#xD;
      the proportions of subjects in each vaccine dosage group that achieve a serum HAI titer of at&#xD;
      least 1:32 one month after the second vaccination; the geometric mean titer (GMT) of serum&#xD;
      HAI antibody against the influenza A/H9N2 virus one month after the second vaccination; the&#xD;
      rates of significant increases in titer between pre- and post-immunization serum samples&#xD;
      (defined as seroconversion-i.e., increase in titer from &lt;1:4 pre-immunization to at least 1:8&#xD;
      after vaccination, or 4-fold or greater increase in titer between pre- and post-immunization&#xD;
      samples) 28 days after each vaccination (days 28 and 56); and the proportion of subjects with&#xD;
      a 4-fold or greater increase in percent HA-specific antibody in nasal wash specimens for each&#xD;
      vaccine group. The study will be a double-blind evaluation of 4 dosage levels of study&#xD;
      vaccine. The 4 dosage levels to be tested are 3.75-, 7.5-, 15-, and 30-mcg of HA of the&#xD;
      vaccine strain with and without MF59 adjuvant. Because all dosage levels are lower than the&#xD;
      total hemagglutinin content of the FLUADÂ® vaccine used in Europe, subjects will be enrolled&#xD;
      into all dosage and adjuvant groups concurrently using a randomized, double-blind study&#xD;
      design. Ninety-six persons 18-34 years of age will be enrolled. A single lot of monovalent&#xD;
      inactivated SA influenza A/H9N2 vaccine will be used throughout the trial. All injections&#xD;
      will be administered in a 0.5-mL volume into the deltoid muscle. Screening and safety&#xD;
      laboratory examinations will be assessed before the first dose and 7 days after each&#xD;
      vaccination. Assessments for reactogenicity will be done for at least 20 minutes after each&#xD;
      vaccination, in the clinic 2 and 7 days after each inoculation, via diary card for seven days&#xD;
      after each vaccination, and via phone or other contact at 7 months after the first&#xD;
      vaccination for any serious adverse events during the entire study period. Serum and nasal&#xD;
      wash samples collected on days 0, 28, and 56 will be used to measure immunogenicity of the&#xD;
      vaccine preparation. Participants will be involved in study related procedures for up to 8&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The frequency and severity of solicited local and systemic adverse events in each vaccine dosage level group.</measure>
    <time_frame>Duration of study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportions of subjects in each vaccine dosage group that achieve a serum HAI titer of at least 1:32.</measure>
    <time_frame>One month after the second vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of significant increases in titer between pre- and post-immunization serum samples 28 days after each vaccination.</measure>
    <time_frame>Days 28 and 56.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The geometric mean titer (GMT) of serum HAI antibody against the influenza A/H9N2 virus.</measure>
    <time_frame>One month after the second vaccination.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects with a 4-fold or greater increase in percent HA-specific antibody in nasal wash specimens for each vaccine group.</measure>
    <time_frame>Nasal wash samples collected on Days 0, 28, and 56.</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1A: 3.75 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 3.75 mcg A/H9N2 with no adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 7.5 mcg A/H9N2 plus MF59 adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3A: 15 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 15 mcg A/H9N2 with no adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 15 mcg A/H9N2 plus MF59 adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 30 mcg A/H9N2 plus MF59 adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4A: 30 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 30 mcg A/H9N2 with no adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2A: 7.5 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 7.5 mcg A/H9N2 with no adjuvant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 subjects to receive 3.75 mcg A/H9N2 plus MF59 adjuvant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza A/H9N2 vaccine</intervention_name>
    <description>A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.</description>
    <arm_group_label>Group 1A: 3.75 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_label>Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 2A: 7.5 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_label>Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 3A: 15 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_label>Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 4A: 30 mcg A/H9N2 no adjuvant</arm_group_label>
    <arm_group_label>Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MF59 adjuvant</intervention_name>
    <description>MF59 adjuvant is an oil-in-water emulsion.</description>
    <arm_group_label>Group 1B: 3.75 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 2B: 7.5 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 3B: 15 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
    <arm_group_label>Group 4B: 30 mcg A/H9N2 plus MF59 adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory, healthy males and non-pregnant female adults 18-34 years of age.&#xD;
&#xD;
          -  Able to give informed consent and available for all study visits.&#xD;
&#xD;
          -  Able to understand and comply with planned study procedures.&#xD;
&#xD;
          -  Women capable of bearing children must utilize an acceptable means of birth control&#xD;
             (abstinence, oral contraceptives (&quot;the pill&quot;), intrauterine devices (IUDs),&#xD;
             contraceptive implants under the skin, or contraceptive injections, or condoms with&#xD;
             foam).&#xD;
&#xD;
          -  On no concomitant medications except contraceptive medications.&#xD;
&#xD;
          -  Normal screening laboratory values.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to eggs or other components of vaccine.&#xD;
&#xD;
          -  Prior receipt of an influenza A/H9N2 vaccine.&#xD;
&#xD;
          -  Abnormal screening laboratory values (laboratory values must be within normal limits).&#xD;
&#xD;
          -  Pregnancy, desire to become pregnant in the next 3 months, or lactation.&#xD;
&#xD;
          -  Immunosuppression as a result of underlying illness or treatment.&#xD;
&#xD;
          -  Use of oral or parenteral steroids, high-dose inhaled steroids (&gt;800 mcg per day of&#xD;
             beclomethasone dipropionate or equivalent), other immunosuppressive or cytotoxic&#xD;
             drugs.&#xD;
&#xD;
          -  Active neoplastic disease or history of any hematologic malignancy.&#xD;
&#xD;
          -  Acute or chronic condition that (in the opinion of the investigator) would render&#xD;
             vaccination unsafe or would interfere with the evaluation of responses (including but&#xD;
             not limited to the following: known chronic liver disease, significant renal disease,&#xD;
             unstable or progressive neurologic disorder, diabetes mellitus, transplant recipient).&#xD;
&#xD;
          -  Use of experimental vaccines or medications within the month prior to study entry, or&#xD;
             expected use of experimental or licensed vaccines or blood/blood products during the 1&#xD;
             month period after each inoculation with study vaccine.&#xD;
&#xD;
          -  Receipt of immunoglobulin or other blood product within 3 months prior to enrollment.&#xD;
&#xD;
          -  Receipt of other licensed vaccines within the preceding 2 weeks (inactivated vaccines)&#xD;
             or 4 weeks (live vaccines).&#xD;
&#xD;
          -  History of a severe reaction following vaccination with a contemporary influenza&#xD;
             vaccine.&#xD;
&#xD;
          -  Subject is enrolled in another clinical trial.&#xD;
&#xD;
          -  Study personnel (those persons identified on study personnel logs).&#xD;
&#xD;
          -  Any condition that in the opinion of the investigator would interfere with the&#xD;
             interpretation or evaluation of the vaccine.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>34 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis. 2006 Nov 1;43(9):1135-42. Epub 2006 Sep 25.</citation>
    <PMID>17029131</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2005</study_first_posted>
  <last_update_submitted>August 26, 2010</last_update_submitted>
  <last_update_submitted_qc>August 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Johnson</name_title>
    <organization>HHS/NIAID/DMID</organization>
  </responsible_party>
  <keyword>Influenza, vaccine, A/H9N2, MF59, adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

